prasinezumab
Jump to navigation
Jump to search
Contraindications
- of no benefit for early Parkinson's disease[1]
Mechanism of action
- monoclonal antibody that targets alpha-synuclein aggregates[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Pagano G et al. Trial of prasinezumab in early-stage Parkinson's disease. N Engl J Med 2022 Aug 4;387:421. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35921451 https://www.nejm.org/doi/10.1056/NEJMoa2202867
Whone A. Monoclonal antibody therapy in Parkinson's disease - The end? N Engl J Med 2022 Aug 4;387:466. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35921458 https://www.nejm.org/doi/10.1056/NEJMe2207681